Founded in 2012, Recbio is an innovative vaccine company with independent research and development technology as its core driving force. It is committed to building a full value chain of innovative vaccines, covering research and development, production and commercialization. The Company has always adhered to the mission of “creating first-class vaccines and protecting human health”. With a strong research and development engine comprising of novel adjuvants, protein engineering, immunological evaluation and other core technology platforms, strategically focusing on disease areas with significant burden such as cervical cancers COVID-19, shingles, adult TB, HFMD and flu etc., the Company has established a high-value product pipeline consisting of 12 vaccine candidates with independent intellectual property rights, in order to meet the under-fulfilled public health needs. For more information, please visit https://www.recbio.cn/.
Dr. Liu Yong founded the group in 2011 and is responsible for the overall management of Recbio.
Dr. Liu received his Ph.D. in pathogen biology from Peking Union Medical College, And completed postdoctoral research in basic medicine at CDC of China. Dr. Liu has over 23 years of experience in the development and commercialization of innovative vaccines. Prior to founding Recbio, he worked as a researcher at CDC in China, where he was in charge of the development of HIV DNA vaccine. He also worked as a visiting scholar and researcher at NIH Vaccine Research and Development Center to conduct special research on HIV. Dr. Liu is the only Asian member of the Global AIDS Vaccine Enterprise Initiative (GHVE) and the Committee of Early Career Researchers (YECIC). Dr. Liu has published more than 60 papers in well-known academic journals and obtained more than 20 invention patents.
Dr. Chen Jianping is in charge of the research and development of Recbio.
Dr. Chen received his Ph.D. in immunology from the Graduate School of The Chinese Center for Disease Control and Prevention, and conducted postdoctoral research at the University of Connecticut and the Medical University of South Carolina. Dr. Chen has over 19 years of research experience in immunology and molecular biology, and over 10 years of experience in vaccine development. Dr. Chen has worked at CDC in China and received an Associate Research Certificate in Immunology from the Ministry of Health in China. Prior to joining Recbio, He served as the Deputy General Manager of Beijing Kangle Defender, responsible for R&D and clinical registration. Dr. Chen was awarded the Second prize of the State Science and Technology Progress Award and the first prize of the Chinese Medical Science and Technology Award by The State Council of China.
Mr. Li Bu is responsible for the daily operations and strategic development of The human resources, IT, administration and procurement business of Recbio.
Mr. Li Bu holds an MBA degree from Kunming University and has over 21 years of experience in human resource management. Prior to joining Recbio, Mr. Li served as general Manager of Kunming Hanyu Business Consulting Co., LTD., and as assistant to the General manager of Watson Biotechnology Co., LTD., a listed vaccine company in China. Mr. Li worked as human resources manager for listed pharmaceutical group Kunming Pharmaceutical Group for more than 6 years.
Mr. Zhou Hongjun is responsible for the industrialization construction and production management of Recbio.
Mr. Zhou holds a master's degree in bioengineering from Kunming University of Science and Technology and has over 20 years of experience in vaccine development, commercialization, manufacturing and quality management. Prior to joining Recbio, he worked for Watson Biotechnology Co., LTD., a listed vaccine company in China, where he led the commercial production of several leading vaccine products, including Hib vaccine, meningitis A+C conjugate vaccine, pneumococcal polysaccharide vaccine 23 and pneumococcal conjugate vaccine 13, and participated in multiple GMP certification procedures at home and abroad. Mr. Zhou was awarded the second prize of science Progress Award twice by Yunnan Provincial People's Government.
Deputy general Manager
CFO and Secretary to the Board
Deputy general Manager
CFO and Secretary to the Board
Ms. Chen Qingqing is responsible for corporate governance and capital operation of Finance, legal affairs, internal audit and internal control, investor relations, etc.
Ms. Chen holds a Master's degree in Business Administration from Peking University and a Master's degree in Economics from Central University of Finance and Economics. She has more than 20 years of experience in comprehensive financial management. Prior to joining Recbio, Ms. Chen served as CFO, Vice President and other financial executives in Tencent, Renren, Shell and Qudian listed companies on the Stock Exchange and New York Stock Exchange. She was responsible for the pre-IPO, IPO preparation and post-IPO management of these companies.
Dr. Zhang Jianhui is responsible for clinical development of Recbio.
Dr.Zhang received M.D. degree from Beijing Medical University, completed postdoctoral research in molecular virology at academy of Military Medical Sciences, and worked as a visiting scholar at University of Regensburg and University of Dusseldorf. Dr. Zhang was a professor at China CDC, responsible for AIDS vaccine laboratory and clinical research, international program management, and was a professor of Oncology and doctoral supervisor at Hebei Medical University. Dr. Zhang has extensive experience in clinical research and registration of innovative vaccines and drugs. Prior to joining Recbio, Dr. Zhang served as head of clinical medicine and CMO at leading pharmaceutical companies sanofi-Genzyme, Merck China R&D Center, Minti China, and Bonasia. Dr. Zhang has published or co-published more than 50 articles in academic journals in immunology and other related fields.
Dr. Hong Kunxue is responsible for formulating and guiding the R&D strategy of Recbio.
Dr. Hong received his Ph.D. degree in genetics from Peking Union Medical College and completed postdoctoral research at CDC in China. Dr. Hung has been a research scholar at the University of California, Los Angeles, a leading academic institution in the United States, and a visiting scholar at the Human Vaccine Institute at Duke University. He has more than 30 years of experience in immunology at the China CDC, and nearly 13 years of experience as a member of the academic committee and degree Committee at the China CDC center for STD/AIDS Prevention and Control. Dr. Hong is a member of the editorial board of Infectious Microorganisms and Diseases. Dr. Hong has published more than 100 articles in academic journals in immunology and other related fields.
Ms. Wang Jing is responsible for the total quality management of Recbio.
Ms. Wang holds a master's degree in bioengineering from Sichuan University and is a senior engineer. She used to work in Chengdu Institute of Biological Products. She has more than 20 years of experience in vaccine r&d, commercial production and quality management, and nearly 10 years of experience as manager of quality management department and quality licensee of vaccine manufacturing enterprises. She has rich experience in vaccine registration and has many successful registration cases. Familiar with the international and domestic GMP audit requirements and standards, organized and passed the WHO PQ on-site inspection and review for several times, good at the integration of ISO quality, environment and occupational health in accordance with the requirements of GMP quality management system construction and operation.
Ms. Feng Yanfei is responsible for the global business development of the company.
Ms. Feng has more than 20 years of experience in biotechnology and innovative pharmaceutical industry in China and the United States, including product development, business development and international market management. Prior to joining Recbio, Ms. Feng served as managing Director of LYFE Capital, where she was responsible for investment in innovative pharmaceuticals. She worked in strategic marketing and business development for AbbVie and Abbott Laboratories International Marketing. She served as Senior Vice President of Business Development and Alliance Management at Eiteng Pharmaceuticals. As the founder and CEO of a Chinese digital healthcare startup company, she has accumulated profound business management experience in the biomedical field.
Mr. Zhou Lei is responsible for the financial management and audit work of Recbio.
Mr. Zhou holds a bachelor's degree in accounting from Jiangsu University of Science and Technology, and obtained intermediate Accountant and Certified Tax Agent certificates. Mr. Zhou is currently certified as a certified Public Accountant. Mr. Zhou has rich professional experience in financial management and tax management of pharmaceutical enterprises. Prior to joining Recbio, He worked for Yangzijiang Pharmaceutical Group Co., LTD., where he served as finance director.
Awards & Certificates
The Philippines has approved an international multicenter Phase II/III trial of the COVID-19 vaccine ReCOV
Recogen, a subsidiary specializing in the field of mRNA infectious vaccine, launched the world's first lyophilized dosage form mRNA vaccine
Successfully list on the main board of the Hong Kong Stock Exchange (SEHK) with stock code: 2179.HK
ReCOV Taizhou production base successfully passed THE EU QP audit
Phase II/III trial of ReCOV sequential booster immunization approved in UAE
Clinical Trial Approval For ReCOV In The PRC
Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines
Approval Of The Comparative Study Betweenrecov And mRNA Vaccines By FDA In The Philippines
Complete B+ round of financing and C round of financing
Launch Phase III clinical trial of recombinant nine-valent HPV vaccine (Hanson's yeast)
Launch Phase I clinical trial of recombinant COVID-19 vaccine in New Zealand
Recbio and Shenzhen Rhegen Biotechnology Co. Ltd. reached strategic cooperation and established a joint venture company Wuhan Recogen Biotechnology Co., Ltd. (Recogen) to jointly develop mRNA vaccine
Obtain the Drug Production License for COVID-19 vaccine issued by Jiangsu Food and Drug Administration.
Starte the construction of production facilities for the industrialization project of HPV vaccine
Complete Series B financing
Complete Phase I clinical trial of recombinant bivalent HPV16/18 vaccine (Hanson's yeast)
Complete Phase I clinical trial of recombinant nine-valent HPV vaccine (Hanson's yeast)
Start COVID-19 vaccine industrialization program
Launch Phase I clinical trial of recombinant nine-valent HPV vaccine (Hanson's yeast)
Complete Series A financing
Receive clinical trial approval for a recombinant bivalent HPV6/11 vaccine (Hanson's yeast)
Receive clinical trial approval for a recombinant nine-valent HPV vaccine (Hanson's yeast)
Receive clinical trial approval for a recombinant bivalent HPV16/18 vaccine (Hanson's yeast)
Launch research and development of recombinant herpes zoster vaccine and establishment of adjuvant platform
Establish and start operation in Taizhou China Pharmaceutical City Vaccine Engineering Center
Sign a Cooperation Agreement on HPV Preventive Vaccine (Recombinant Hanson's Yeast) with Beijing Anbaisheng.
Beijing Anbaisheng Biotechnology Co., LTD. (the first operating entity of the company) was established